Acorda Therapeutics (ACOR) Stock Price, News & Analysis

Company Overview

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.66 to $15.60
• 52-Week Range: N/A
• Volume: 416,900 shs
• Average Volume: 119,299 shs
• Market Capitalization: $820 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ACOR Stock Analysis - Frequently Asked Questions

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics, Inc. (NASDAQ:ACOR) announced its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($28.60) EPS for the quarter, beating analysts' consensus estimates of ($31.20) by $2.60. The biopharmaceutical company had revenue of $31.46 million for the quarter, compared to analyst estimates of $30.57 million. Acorda Therapeutics had a negative net margin of 214.95% and a negative trailing twelve-month return on equity of 2,206.93%.

When did Acorda Therapeutics' stock split?

Shares of Acorda Therapeutics reverse split before market open on Monday, June 5th 2023.The 1-20 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Acorda Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Acorda Therapeutics investors own include Meta Platforms (META), Sangamo Therapeutics (SGMO), GE Aerospace (GE), NVIDIA (NVDA), Exxon Mobil (XOM), Energy Transfer (ET) and CymaBay Therapeutics (CBAY).

Company Calendar

• Last Earnings: 11/09/2021
• Today: 7/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ACOR
• CIK: 1008848
• Web: www.acorda.com
• Phone: (914) 347-4300
• Fax: 914-347-4560
• Employees: 111
• Year Founded: 1995

Profitability

• EPS (Trailing Twelve Months): ($203.83)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$252.85 million
• Net Margins: -214.95%
• Pretax Margin: -251.65%
• Return on Equity: -2,206.93%
• Return on Assets: -83.28%

Debt

• Debt-to-Equity Ratio: 3.07
• Current Ratio: 0.33
• Quick Ratio: 0.26

Sales & Book Value

• Annual Sales: $117.63 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 0.02
• Book Value: ($127.17) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,240,000
• Free Float: 1,210,000
• Market Cap: $820 thousand
• Optionable: No Data
• Beta: 1.40